482 articles in this topic
Science Translational Medicine publishes an erratum for a 2024 study on GDP-mannose and antitumor immunity in triple-negative breast cancer.
A correction to a landmark case-control study reexamines vitamin D's role in breast cancer risk among Saudi Arabian women.
USP20 drives immune exhaustion in pancreatic cancer by hijacking cholesterol and autophagy — and blocking it triples treatment response in preclinical models.
A lipid metabolism enzyme called SMPD1 anchors the deadliest cancer mutation to the cell membrane — and blocking it may finally crack KRAS.
A large multicenter study finds GLP-1 receptor agonists dramatically outperform DPP-4 inhibitors in preventing HCC recurrence and death post-resection.
The COMPETE trial shows radioligand therapy extends progression-free survival by nearly 10 months vs. standard targeted therapy in GEP NETs.
New research reveals how a high-fat diet rewires tumor-to-nerve communication, accelerating cachexia — the devastating wasting syndrome that kills cancer patients.
Harvard's COMPASS model forecasts which patients will respond to immune checkpoint inhibitors with striking accuracy across seven cancer types.
A newly discovered enzyme-driven feedback cycle helps liver tumors suppress immunity and resist checkpoint blockade — and blocking it may help.
A neoantigen peptide vaccine targeting IDH1-R132H mutation doubled median survival in grade IV astrocytoma patients vs. historical benchmarks.
A comprehensive review maps the distinct molecular mechanisms and emerging therapies across all four thyroid cancer subtypes.
New research links faster biological aging in younger adults to the alarming rise in cancers before age 50.
